Monoclonal antibodies as therapeutics in human malignancies

Future Oncology

Volumn 10, Issue 4, 2014, Pages 609-636

  Pandey, Manjari ^a   Mahadevan, Daruka ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

antibody drug conjugates; antibody engineering; antibody targets; clinical trials; monoclonal antibodies; targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN GROWTH HORMONE; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; GENE EXPRESSION PROFILING; GENETIC ENGINEERING; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SOLID TUMOR; ANIMAL; BIOTECHNOLOGY; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; HEMATOLOGIC NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ENGINEERING;

EID: 84899485035     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.197     Document Type: Review

References (173)

1. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8(6), 473-480 (2008
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975
3. Nadler LM, Stashenko P, Hardy R et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-Associated antigen. Cancer Res. 40(9), 3147-3154 (1980
4. Galluzzi L, Vacchelli E, Fridman WH et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 1(1), 28-37 (2012
5. Maloney DG, Grillo-Lopez AJ, White CA. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6), 2188-2195 (1997
6. Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell 148(6), 1081-1084 (2012
7. Zhao X, Lapalombella R, Joshi T et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7), 2569-2577 (2007
8. Pucca MB, Bertolini TB, Barbosa JE, Galina SVR, Porto GS. Therapeutic monoclonal antibodies: ScFv patents as a marker of a new class of potential biopharmaceuticals. Braz. J. Pharm. Sci. 47, 31-38 (2011
9. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug Discov. 8(3), 226-234 (2009
10. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2(2), 181-189 (2010
11. Roopenian DC, Akilesh S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7(9), 715-725 (2007
12. Nagashima H, Ootsubo M, Fukazawa M, Motoi S, Konakahara S, Masuho Y. Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains. J. Biosci. Bioeng. 111(4), 391-396 (2011
13. Natsume A M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68(10), 3863-3872 (2008
14. Riley CJ, Engelhardt KP, Saldanha JW et al. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 69(5), 1933-1940 (2009
15. Jiang XR, Song A, Bergelson S et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug Discov. 10(2), 101-111 (2011
16. Li F, Ravetch JV Inhibitory Fcgamma receptor engagement drives adjuvant and anti-Tumor activities of agonistic CD40 antibodies. Science 333(6045), 1030-1034 (2011
17. Marasco WA, Sui J The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnol. 25(12), 1421-1434 (2007
18. Sullivan M, Kaur K, Pauli N, Wilson PC. Harnessing the immune system's arsenal: Producing human monoclonal antibodies for therapeutics and investigating immune responses. F1000 Biol Rep. 3, 17 (2011
19. Chowdhury PS, Wu H. Tailor-made antibody therapeutics. Methods 36(1), 11-24 (2005
20. Roque AC, Lowe CR, Taipa MA. Antibodies and genetically engineered related molecules: Production and purification. Biotechnol. Prog. 20(3), 639-654 (2004
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000
22. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144(5), 646-674 (2011
23. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 13(6), 472-482 (2008
24. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 136(5), 823-837 (2009
25. Guo K, Li J, Tang JP et al. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci. Transl. Med. 3(99), 99ra85 (2011
26. Guo K, Tang JP, Jie L et al. Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3(2), 158-171 (2012
27. Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J. 8(3), e466-e478 (2006
28. Polakis P. Arming antibodies for cancer therapy. Curr. Opin. Pharmacol. 5(4), 382-387 (2005
29. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol. Cancer Ther. 3(11), 1493-1501 (2004
30. Yarden Y, Pines G. The ERBB network: At last, cancer therapy meets systems biology. Nat. Rev. Cancer 12(8), 553-563 (2012
31. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27(5), 663-671 (2009
32. Van Cutsem E, Kohne CH, Lang I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29(15), 2011-2019 (2011
33. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a Phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11(1), 21-28 (2010
34. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008
35. Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658-1664 (2007
36. Douillard JY, Siena S, Cassidy J et al. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol. 28(31), 4697-4705 (2010
37. Peeters M, Price TJ, Cervantes A et al. Randomized Phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28(31), 4706-4713 (2010
38. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001
39. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005
40. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005
41. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010
42. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012
43. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004
44. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007
45. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006
46. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733-4740 (2009
47. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2009
48. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007
49. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008
50. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 28(20), 3239-3247 (2010
51. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473-2483 (2011
52. Perren TJ, Swart AM, Pfisterer J et al. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484-2496 (2011
53. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499-3506 (2012
54. De La Cruz-Merino L, Grande-Pulido E, Albero-Tamarit A, Codes-Manuel De Villena ME. Cancer and immune response: Old and new evidence for future challenges. Oncologist 13(12), 1246-1254 (2008
55. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238), 985-988 (1995
56. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7(2), 95-106 (2007
57. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat. Rev. Drug Discov. 10(6), 411-412 (2011
58. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
59. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011
60. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28(35), 5132-5139 (2010
61. Lipton A, Fizazi K, Stopeck AT et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, Phase 3 trials. Eur. J. Cancer 48(16), 3082-3092 (2012
62. Heiss MM, Murawa P, Koralewski P et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized Phase II/III trial. Int. J. Cancer 127(9), 2209-2221 (2010
63. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22(47), 7359-7368 (2003
64. Van Meerten T, Hagenbeek A. CD20-Targeted therapy: The next generation of antibodies. Semin. Hematol. 47(2), 199-210 (2010
65. Alduaij W, Illidge TM The future of anti-CD20 monoclonal antibodies: Are we making progress? Blood 117(11), 2993-3001 (2011
66. US FDA approval for rituximab. www.cancer.gov/cancertopics/druginfo/ fda-rituximab
67. Lemery SJ, Zhang J, Rothmann MD et al. US Food and Drug Administration approval: Ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin. Cancer Res. 16(17), 4331-4338 (2010
68. Grillo-Lopez AJ. Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther. 2(5), 485-493 (2002
69. Davies AJ. Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view. Q. J. Nucl. Med. Mol. Imaging 48(4), 305-316 (2004
70. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Ann. Rev. Med. 64, 15-29 (2013
71. De Claro RA, Mcginn K, Kwitkowski V et al. US Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin. Cancer Res. 18(21), 5845-5849 (2012
72. Newland AM, Li JX, Wasco LE, Aziz MT, Lowe DK. Brentuximab vedotin: A CD30-directed antibody-cytotoxic drug conjugate. Pharmacotherapy 33(1), 93-104 (2013
73. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur. J. Immunol. 29(11), 3440-3449 (1999
74. Bross PF, Beitz J, Chen G et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6), 1490-1496 (2001
75. Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group Study S0106: An international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114(22), 790 (2009
76. Ravandi F, Estey EH, Appelbaum FR et al. Gemtuzumab ozogamicin: Time to resurrect? J. Clin. Oncol. 30(32), 3921-3923 (2012
77. Feldman EJ, Brandwein J, Stone R et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23(18), 4110-4116 (2005
78. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single-Agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13(2), 167-174 (2008
79. Fiegl M, Erdel M, Tinhofer I et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: A retrospective study on various cytogenetic risk categories. Ann. Oncol. 21(12), 2410-2419 (2010
80. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostatespecific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44(4), 610-617 (2003
81. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostatespecific membrane antigen expression in vivo. J. Nucl. Med. 51(8), 1293-1300 (2010
82. Radioimmunotherapy in prostate cancer using 177Lu-J591 antibody. http://clinicaltrials.gov/show/ NCT00538668
83. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-Agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010
84. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013
85. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H et al. PET with the 89Zr-labeled transforming growth factor-beta antibody fresolimumab in tumor models. J. Nucl. Med. 52(12), 2001-2008 (2011
86. Anti-TGF monoclonal antibody (GC1008) in relapsed malignant pleural mesothelioma. http://clinicaltrials.gov/show/NCT01112293
87. Fresolimumab and radiotherapy in metastatic breast cancer. http://clinicaltrials.gov/show/NCT01401062
88. Saxena B, Sundaram ST, Walton W et al. Differentiation between the EGFR antibodies necitumumab, cetuximab and panitumumab: In vitro biological and binding activities. J. Clin. Oncol. 29(Suppl. 15), Abstract e13030 (2011
89. First-line treatment of patients with stage IV nonsquamous non-small cell lung cancer with necitumumab (IMC-11F8) and pemetrexedcisplatin (INSPIRE). http://clinicaltrials.gov/show/NCT00982111
90. First-line treatment of participants with stage IV squamous non-small cell lung cancer with necitumumab and gemcitabine-cisplatin (SQUIRE). http://clinicaltrials.gov/show/NCT00981058
91. Ramakrishnan MS, Eswaraiah A, Crombet T et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 1(1), 41-48 (2009
92. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010
93. Krop IE, Lorusso P, Miller KD et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30(26), 3234-3241 (2012
94. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012
95. A Phase I study of LJM716 in squamous cell carcinoma of head and neck, or HER2+ breast cancer or gastric cancer. http://clinicaltrials.gov/show/ NCT01598077
96. Clinicaltrials.gov. www.clinicaltrials.gov
97. Peeters M, Strickland AH, Lichinitser M et al. A randomised, double-blind, placebo-controlled Phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br. J. Cancer 108(3), 503-511 (2013
98. Eatock MM, Tebbutt NC, Bampton CL et al. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann. Oncol. 24(3), 710-718 (2013
99. Tap WD, Van Tine BA, Elias AD et al. A Phase Ib/II study evaluating the efficacy of doxorubicin (D) with or without a human anti-PDGFRa monoclonal antibody olaratumab (IMC-3G3) in the treatment of advanced soft tissue sarcoma (STS). J. Clin. Oncol. 30(Suppl.), Abstract TPS10099 (2012
100. A study of IMC-3G3 in soft tissue sarcoma. http://clinicaltrials.gov/ show/ NCT01185964
101. A study of IMC-3G3 in previously treated patients with unresectable and/or metastatic gastrointestinal stromal tumors. http://clinicaltrials.gov/ show/ NCT01316263
102. Peters S, Adjei AA. MET: A promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 9(6), 314-326 (2012
103. Patnaik A, Weiss GJ, Papadopoulos K et al. Phase I study of SCH900105 (SC), an anti-heaptocyte growth factor (HGF) monoclonal ab (Mab), as a single agent and in combination with erlotinnib (E) in patients with advanced solid tumors. J. Clin. Oncol. 28(Suppl. 15), Abstract 2525 (2010
104. Tan E, Park K, Lim WT et al. Phase IB study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J. Clin. Oncol. 29(Suppl.), Abstract 7571 (2011
105. Mok T, Tan E, Park K et al. Randomized Phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J. Clin. Oncol. 29(Suppl.), Abstract TPS213 (2011
106. Jones SF, Cohen RB, Bendell J C et al. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human Phase I dose-escalation study. J. Clin. Oncol. 28(Suppl. 15), Abstract 3081 (2010
107. Gordon MS, Sweeney CS, Mendelson DS et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factorneutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin. Cancer Res. 16(2), 699-710 (2010
108. Rosen PJ, Sweeney CJ, Park DJ et al. A Phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin. Cancer Res. 16(9), 2677-2687 (2010
109. Eng C, Van Cutsem E, Nowara A et al. A randomized, Phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-Type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. J. Clin. Oncol. 29(Suppl. 15), Abstract 3500 (2011
110. Wen PY, Schiff D, Cloughesy TF et al. A Phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 13(4), 437-446 (2011
111. Schoffski P, Garcia JA, Stadler WM et al. A Phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 108(5), 679-686 (2011
112. Ryan CJ, Rosenthal M, Ng S et al. Targeted MET inhibition in castration-resistant prostate cancer: A randomized Phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin. Cancer Res. 19(1), 215-224 (2013
113. Spigel DR, Ervin TJ, Ramlau R et al. Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J. Clin. Oncol. 29(Suppl. 15), 7505 (2011
114. Spigel DR, Edelman MJ, Mok T et al. The MetLUNG study: A randomized, doubleblind, Phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl. 15), Abstract TPS7616 (2012
115. Study evaluating the safety and efficacy of onartuzumab (Metmab) and/or bevacizumab in combination with paclitaxel in patients with metastatic, triple-negative breast cancer. http://clinicaltrials.gov/show/ NCT01186991
116. FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer. http://clinicaltrials. gov/show/NCT01418222
117. A study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and Met-positive gastroesophageal cancer (MetGastric). http://clinicaltrials.gov/show/ NCT01662869
118. Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer - preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37(5), 430-439 (2010
119. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 19(5), 997-1008 (2013
120. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19(5), 1044-1053 (2013
121. Tseng D, Volkmer J-P, Willingham SB et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc. Natl Acad. Sci. USA 110(27), 11103-11108 (2013
122. Wu YL, Liang J, Zhang W, Tanaka Y, Sugiyama H. Immunotherapies: The blockade of inhibitory signals. Int. J. Biol. Sci. 8(10), 1420-1430 (2012
123. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
124. Study of nivolumab (BMS-936558) in combination with gemcitabine/ cisplatin, pemetrexed/cisplatin, carboplatin/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB/IV non-small cell lung cancer (NSCLC) (CheckMate 012). http:// clinicaltrials.gov/show/NCT01454102
125. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
126. Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616-622 (2013
127. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: A historical perspective. Pharmacol. Ther. 136(3), 334-342 (2012
128. Topp MS, Gokbuget N, Zugmaier G et al. Long-Term follow-up of hematologic relapse-free survival in a Phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 120(26), 5185-5187 (2012
129. Younes A, Kim S, Romaguera J et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J. Clin. Oncol. 30(22), 2776-2782 (2012
130. A safety study of SGN-CD19A for B-cell lymphoma. http://clinicaltrials. gov/show/NCT01786135
131. A safety study of SGN-CD19A for leukemia and lymphoma. http://clinicaltrials.gov/show/NCT01786096
132. Poe JC, Tedder TF. CD22 and Siglec-G in B cell function and tolerance. Trends Immunol. 33(8), 413-420 (2012
133. Younes A. Beyond chemotherapy: New agents for targeted treatment of lymphoma. Nat. Rev. Clin. Oncol. 8(2), 85-96 (2011
134. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 21(16), 3051-3059 (2003
135. Micallef IN, Maurer MJ, Wiseman GA et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118(15), 4053-4061 (2011
136. Fayad L, Offner F, Smith MR et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: Results of a Phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J. Clin. Oncol. 31(5), 573-583 (2013
137. A study of inotuzumab ozogamicin plus rituximab for relapsed/refractory aggressive non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. http://clinicaltrials.gov/show/NCT01232556
138. Advani R, Lebovic D, Brunvand M et al. A Phase I study of DCDT2980S, an antibody-drug conjugate (ADC) targeting CD22, in relapsed or refractory B-cell non-hodgkin's lymphoma (NHL). Blood 120(21), Abstract 59 (2012
139. A study of the safety and pharmacokinetics of escalating doses of DCDT2980S in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma and chronic lymphocytic leukemia and DCDT2980S in combination with rituximab in patients with relapsed or refractory B-cell non Hodgkin's lymphoma. http://clinicaltrials.gov/show/NCT01209130
140. Kreitman RJ, Tallman MS, Robak T et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 30(15), 1822-1828 (2012
141. Davis RE, Ngo VN, Lenz G et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277), 88-92 (2010
142. Palanca-Wessels MC, Flinn IW, Sehn LH et al. A Phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-hodgkin's lymphoma (NHL). Blood 120(21), Abstract 56 (2012
143. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 23(6), 285-290 (2002
144. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in B cell-derived neoplasms. Am. J. Clin. Pathol. 134(5), 726-733 (2010
145. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: Implications for anti-CD200 therapy. J. Immunol. 180(2), 699-705 (2008
146. Mahadevan D, Lanasa MC, Whelden M et al. 2465 first-in-human phase i dose escalation study of a humanized anti-CD200 antibody (samalizumab) in patients with advanced stage B cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM). Presented at: 53rd American Society of Hematology Annual Meeting and Exposition. CA, USA, 10-13 December 2010 (Abstract 2456
147. Sanz-Rodriguez F, Hidalgo A, Teixido J
148. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br. J. Haematol. doi:10.1111/j.1365-2141.2011.08790.x (2011)(Epub ahead of print
149. Lonial S, Vij R, Harousseau JL et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol. 30(16), 1953-1959 (2012
150. Jakubowiak AJ, Benson DM, Bensinger W et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/ refractory multiple myeloma. J. Clin. Oncol. 30(16), 1960-1965 (2012
151. PH III study of lenalidomide and dexamethasone with or without elotuzumab to treat previously untreated multiple myeloma (ELO 1 substudy). http://clinicaltrials.gov/show/NCT01891643
152. Wang Y, Pivonka P, Buenzli PR, Smith DW, Dunstan CR. Computational modeling of interactions between multiple myeloma and the bone microenvironment. PLoS ONE 6(11), e27494 (2011
153. Voorhees PM, Chen Q, Kuhn DJ et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13(21), 6469-6478 (2007
154. Voorhees PM, Manges RF, Sonneveld P et al. A Phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 161(3), 357-366 (2013
155. Orlowski RZ, Gercheva L, Williams C et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. J. Clin. Oncol. 30(Suppl.), Abstract 8018 (2012
156. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 67(3), 871-875 (2007
157. Malavasi F, Deaglio S, Funaro A et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88(3), 841-886 (2008
158. De Weers M, Tai YT, Van Der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840-1848 (2011
159. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a doseescalation Phase I/II Study. Blood 120(21), Abstract 73 (2012
160. Phase 1 SAR650984 combination with lenalidomide (LenCombo). http://clinicaltrials.gov/show/NCT01749969
161. Dose escalation study of Anti-CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies. http://clinicaltrials.gov/show/ NCT01084252
162. Brown VK, Ogle EW, Burkhardt AL, Rowley RB, Bolen JB, Justement LB. Multiple components of the B cell antigen receptor complex associate with the protein tyrosine phosphatase, CD45. J. Biol. Chem. 269(25), 17238-17244 (1994
163. Donor peripheral blood stem cell transplant and pretargeted radioimmunotherapy in treating patients with high-risk advanced acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. http://clinicaltrials.gov/show/NCT00988715
164. Vallera DA, Sicheneder AR, Taras EP et al. Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody. Cancer Biother. Radiopharm. 22(4), 488-500 (2007
165. Yttrium Y90 anti-CD45 monoclonal antibody AHN-12 in treating patients with advanced leukemia. http://clinicaltrials.gov/show/ NCT00618696
166. AHN-12 biodistribution in advanced leukemia. http://clinicaltrials.gov/ show/NCT01207076
167. Guan M, Liu L, Zhao X et al. Copy number variations of EphA3 are associated with multiple types of hematologic malignancies. Clin. Lymphoma Myeloma Leuk. 11(1), 50-53 (2011
168. Study of KB004 in subjects with hematologic malignancies. http://clinicaltrials.gov/show/ NCT01211691
169. Chung CH, O'Neil BH. Infusion reactions to monoclonal antibodies for solid tumors: Immunologic mechanisms and risk factors. Oncology 23(2 Suppl. 1), 14-17 (2009
170. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9(4), 325-338 (2010
171. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev. Clin. Immunol. 7(1), 55-63 (2011
172. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-Alpha-1,3-galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008
173. Vadas P, Gold M, Perelman B et al. Platelet-Activating factor, PAF acetylhydrolase, and severe anaphylaxis. N. Engl. J. Med. 358(1), 28-35 (2008